Wegovy, a medication approved by the FDA for chronic weight management and certain cardiovascular conditions, has gained attention for its potential in long-term weight loss. However, as with any drug, questions persist about its safety over extended periods. In this article, we delve into the current understanding of Wegovy’s long-term safety, its side effects, and its effectiveness, while comparing it with similar medications such as Ozempic.
Safety of Long-Term Use: What We Know
Since its approval in 2021, Wegovy (semaglutide) has been recognized as a safe and effective treatment for obesity and related conditions. In 2024, its use was further expanded to include the reduction of cardiovascular risks in adults with heart disease and overweight or obesity. This broader approval has sparked interest in the drug’s long-term safety.
While clinical trials and real-world data suggest that serious adverse effects are rare, long-term studies focused on Wegovy’s potential risks are still needed. Research to date points to a low likelihood of severe issues, but potential concerns like pancreatitis, gallbladder disease, and kidney damage have emerged as points of discussion for healthcare providers and patients alike.
Side Effects of Wegovy
As with any drug, Wegovy comes with a range of potential side effects, the majority of which are mild to moderate. Based on clinical trial data, gastrointestinal (GI) issues, including nausea, diarrhea, and gas, top the list of common side effects. Other frequent issues reported by users include:
- Headache
- Fatigue
- Common cold symptoms
- Dizziness
- Low blood sugar (in individuals with type 2 diabetes)
More serious side effects, although less common, have been linked to Wegovy use. These include:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder disease
- Kidney injury
- Retinal problems in diabetic patients
- Appendicitis
- A possible increased risk of thyroid cancer (which is highlighted by a boxed warning)
Clinical Trials and Side Effect Data
Clinical trials for Wegovy involved 2,116 adults with obesity or overweight. In these studies, 6.8% of participants on Wegovy discontinued treatment due to side effects, with nausea, vomiting, and diarrhea being the most frequently reported issues. Notably, side effects were more prominent when participants increased their dose of Wegovy.
For cardiovascular outcomes, longer trials lasting up to 37 months found that those on Wegovy were twice as likely to stop treatment compared to those on a placebo, again due to side effects.
In addition to clinical trial reports, voluntary post-marketing side effect reports have revealed rare but serious complications, including necrotizing pancreatitis (a potentially fatal condition) and ileus, a temporary loss of normal intestinal movement.
Comparing Wegovy and Ozempic
Wegovy and Ozempic both contain the same active ingredient—semaglutide—but differ in dosage and intended use. Wegovy is specifically approved for weight loss in individuals aged 12 and older, while Ozempic, although also containing semaglutide, is primarily used for managing type 2 diabetes. It is not FDA-approved for weight loss in younger populations (under 18 years old), though some healthcare providers may prescribe it off-label for this purpose.
While both medications share similar safety profiles, the differing uses and doses mean that side effects may vary. Ozempic’s safety and efficacy for weight loss in individuals under 18 have not been established, limiting its use compared to Wegovy for this purpose.
Who Should Take Wegovy?
Wegovy is typically prescribed for adults and children 12 years and older who have obesity, or for adults with overweight and at least one related health condition such as type 2 diabetes. Additionally, the drug is approved for reducing the risk of major cardiovascular events in adults with heart disease and obesity or overweight.
Who Should Avoid Wegovy?
Certain groups should not take Wegovy due to potential risks. Most notably, individuals who are pregnant should avoid the medication, as it may harm the fetus. Those planning to become pregnant should stop taking Wegovy at least two months before conception.
Wegovy also carries a boxed warning regarding the risk of thyroid cancer, particularly in individuals with a family history of medullary thyroid carcinoma (MTC) or a genetic condition called multiple endocrine neoplasia type 2 (MEN2), which predisposes people to thyroid cancer. Those with these risk factors should not use Wegovy, and a thorough discussion with a healthcare provider is essential to assess personal safety.
Conclusion
Wegovy is generally considered safe for long-term use, with its benefits in weight management and cardiovascular health outweighing the risks for most patients. However, as with any medication, it is crucial for individuals to consult with their healthcare providers about potential side effects and whether Wegovy is suitable for their specific health conditions. The current evidence supports its safety for long-term use, but more comprehensive research is needed to fully understand its long-term impact.
If side effects occur, healthcare providers can assist in adjusting the treatment plan, ensuring that patients can find the safest and most effective course of action for their health goals.
Related Topics:
What Are Weight Loss Drugs Suitable for Busy Lives
